Marinomed Biotech AG Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	7.69	4.75	9.18	11.28	11.63
Revenue Growth (YoY)	62.02%	-48.31%	-18.56%	-3.03%	43.12%
Cost of Revenue	1.4	3.78	8.04	9.14	10.2
Gross Profit	6.29	0.96	1.14	2.14	1.42
Selling, General & Admin	3.99	4.82	5.05	4.85	4.46
Depreciation & Amortization Expenses	0.31	1.06	0.68	0.67	0.61
Other Operating Expenses	-16.73	2.7	1.92	2.37	2.07
Total Operating Expenses	-12.42	8.59	7.64	7.89	7.14
Operating Income	18.71	-7.62	-6.5	-5.75	-5.72
Interest Income	0	0.02	0.86	1.19	0
Interest Expense	-543.31	-7.92	-2.52	-2.67	-1.55
Other Non-Operating Income (Expense)	0	-0.02	-	-	-
Total Non-Operating Income (Expense)	-543.31	-7.91	-1.66	-1.48	-1.55
Pretax Income	18.12	-15.52	-6.79	-6.39	-5.69
Provision for Income Taxes	0.11	-0.1	-0	-0.01	-0.2
Net Income	18.02	-15.42	-6.79	-6.4	-5.89
Net Income to Common	18.02	-15.42	-6.79	-6.4	-5.89
Shares Outstanding (Basic)	2	2	2	1	1
Shares Outstanding (Diluted)	2	2	2	1	1
Shares Change (YoY)	3.46%	17.14%	1.29%	1.56%	0.31%
EPS (Basic)	9.79	-8.67	-4.50	-4.30	-4.00
EPS (Diluted)	9.79	-8.67	-4.50	-4.30	-4.00
Free Cash Flow	-1.1	-2.4	-4.66	-5.43	-5.79
Free Cash Flow Per Share	-0.60	-1.35	-3.07	-3.62	-3.92
Gross Margin	81.74%	20.28%	12.45%	18.98%	12.25%
Operating Margin	243.29%	-160.61%	-70.79%	-51.01%	-49.19%
Profit Margin	234.27%	-324.76%	-73.99%	-56.74%	-50.67%
FCF Margin	-14.30%	-50.56%	-50.71%	-48.16%	-49.75%
EBITDA	18.71	-7.62	-5.82	-5.08	-5.11
EBITDA Margin	243.29%	-160.61%	-63.40%	-45.07%	-43.95%
EBIT	18.71	-7.62	-6.5	-5.75	-5.72
EBIT Margin	243.29%	-160.61%	-70.79%	-51.01%	-49.19%
Effective Tax Rate	0.59%	0.64%	0.06%	0.11%	3.46%